Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Marksans Pharma Limited (MARKSANS.NS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 53.9 M | -51,086,715 | 70.78 M | 318.87 M | 221.53 M |
| 2022 | 49.81 M | -30,864,028 | 50.59 M | 260.53 M | 199.26 M |
| 2021 | 48.95 M | -28,008,036 | 49.61 M | 195.07 M | 142.87 M |
| 2020 | 32.91 M | -20,847,599 | 38.41 M | 146.09 M | 107.31 M |
| 2019 | 29.02 M | -7,549,225 | 29.46 M | 106.67 M | 70.2 M |